Background: Carisoprodol (Somadril®) is a centrally acting skeletal muscle relaxant that is commonly used to treat serious musculoskeletal disorders. Carisoprodol's mechanism of action is unknown and it is often attributed to its active metabolite, meprobamate.
Objective: This study aimed to detect histopathological and immunohistochemical changes in the tissues of the splenic pregnant rats treated orally with Carisoprodol (Soma). Method: Thirty pregnant female albino rats were randomly categorized into three groups. The first group was a negative control and administered oral doses of distilled water. The other two groups were administered oral doses of carisoprodol in the distilled water equivalent to 10.8 mg and 21.6 mg/100g body weight/day respectively for 15 days from the 6^th day to the 20^th day of gestation.
Results: Histological and immunohistochemical studies have been performed on the tissue of the spleen to detect histopathological and immunohistochemical changes. Compared to untreated (negative control) and pregnant rats treated with carisoprodol, the treated rats showed numerous histopathological and immunochemical changes. Conclusion: Treatment of pregnant rats with carisoprodol has induced many atrophic changes in the tissue of the spleen in pregnant rats, so the use of this drug during pregnancy should be under strict protection.